Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma / 대한이비인후과학회지
Korean Journal of Otolaryngology - Head and Neck Surgery
;
: 487-498, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-760161
ABSTRACT
After FDA approval of cetuximab at 2006, receptor tyrosine kinase, including an epidermal growth factor receptor, blocking agents have been evaluated for head and neck squamous cell carcinoma (HNSCC). Agents targeting PI3K/Akt/mTOR, IL-6/JAK/STAT3, vascular endothelial growth factor receptor, and cyclin D-CDK-4/6-INK4/Rb pathway have developed. Most of them have failed to demonstrate better treatment outcome in recurrent and/or metastatic (R/M) HNSCC than conventional chemotherapy. Since a pivotal role of PD-1/PD-L1 pathway in immunological tumor microenvironment was revealed, the immune checkpoint inhibitors, including pembrolizumab and nivolumab, have opened new paradigm of cancer treatment modality and propagates other immune-based therapies for R/M HNSCC. Various types of combination trials consisting of immunotherapy with other class of immunotherapy, targeted agents, radiation therapy, or conventional chemotherapy have been under investigation to improve treatment outcome. Biomarker studies to find an optimal candidate for the newly developed agents are accompanied. These clinical trials lead to tailored approach based on immunotherapy with precision medicine is expected to lead to promising results.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Proteínas Tirosina Quinases
/
Carcinoma de Células Escamosas
/
Resultado do Tratamento
/
Ciclinas
/
Receptores de Fatores de Crescimento do Endotélio Vascular
/
Tratamento Farmacológico
/
Células Epiteliais
/
Medicina de Precisão
/
Terapia de Alvo Molecular
/
Microambiente Tumoral
Tipo de estudo:
Estudo prognóstico
Idioma:
Coreano
Revista:
Korean Journal of Otolaryngology - Head and Neck Surgery
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS